Cara Therapeutics, Inc.
CARA
Κατάταξη σε μετοχές
#9889
Cara Therapeutics, Inc. is an early-stage biopharmaceutical firm operating... Cara Therapeutics, Inc. is an early-stage biopharmaceutical firm operating primarily within the United States. Its core business involves discovering and commercializing novel drug compounds, with a particular emphasis on addressing itching (pruritus) and pain by selectively modulating kappa opioid receptors. The company's therapeutic pipeline includes potential medicines designed to interact with the body's peripheral nervous system and immune cells. KORSUVA (difelikefalin), an injectable formulation, stands as their flagship product. It is approved for treating moderate-to-severe pruritus linked to chronic kidney disease in adult patients undergoing hemodialysis. Additionally, Cara Therapeutics is advancing an oral version of KORSUVA (difelikefalin) through its pipeline. This oral candidate has successfully completed Phase II clinical trials for relieving pruritus associated with atopic dermatitis and chronic kidney disease not requiring dialysis (NDD-CKD). It is also currently undergoing Phase II evaluation for pruritus related to chronic liver disease (specifically primary biliary cholangitis) and for notalgia paresthetica. The company has established international licensing agreements: one with Maruishi Pharmaceutical Co., Ltd for the development, production, and commercialization of difelikefalin-containing products targeting acute pain and uremic pruritus in Japan, and another with Chong Kun Dang Pharmaceutical Corporation for similar activities concerning difelikefalin products in South Korea. Cara Therapeutics, Inc. was established in 2004 and is headquartered in Stamford, Connecticut.
Τιμή μετοχής
$15.96
Τελευταίος συγχρονισμός: 2025-04-15
Κεφαλαιοποίηση
$875.31M
Αλλαγή (1 ημέρα)
-4.14%
Αλλαγή (1 έτος)
-0.19%
Χώρα
US
Εμπόριο Cara Therapeutics, Inc. (CARA)
Κατηγορία
Healthcare
Κεφαλαιοποίηση αγοράς του Cara Therapeutics, Inc.(CARA)
Κεφαλαιοποίηση: $875.31M
Μέχρι το October 2026, η Cara Therapeutics, Inc. έχει χρηματιστηριακή αξία $875.31M. Αυτό καθιστά τη Cara Therapeutics, Inc. την 9889th πιο πολύτιμη εταιρεία στον κόσμο βάσει της κεφαλαιοποίησης σύμφωνα με τα δεδομένα μας. Η χρηματιστηριακή κεφαλαιοποίηση είναι η συνολική αγοραία αξία των μετοχών μιας εισηγμένης εταιρείας και χρησιμοποιείται συνήθως για να προσδιοριστεί η αξία μιας εταιρείας.
Ιστορικό κεφαλαιοποίησης αγοράς της Cara Therapeutics, Inc. από 2018 έως 2026
CARA σε σύγκριση με τα 5 πιο δημοφιλή stocks
| Η τιμή για CARA | Το περιουσιακό στοιχείο B | Η κεφαλαιοποίηση αγοράς του B | Αποτελέσματα | |
|---|---|---|---|---|
$3,475,692
$24.33M
|
$5.289T | +21,736,563.41% | ||
|
$3,272,685
$24.33M
|
$4.980T | +20,466,970.20% | ||
|
$2,743,919
$24.33M
|
$4.175T | +17,160,118.48% | ||
|
$2,603,836
$24.33M
|
$3.962T | +16,284,049.59% | ||
|
$1,860,003
$24.33M
|
$2.830T | +11,632,186.77% |
